Literature DB >> 21126790

Incidence and mortality of alcoholic hepatitis in Denmark 1999-2008: a nationwide population based cohort study.

Thomas Damgaard Sandahl1, Peter Jepsen, Karen Louise Thomsen, Hendrik Vilstrup.   

Abstract

BACKGROUND & AIMS: Alcoholic hepatitis is an acute life- and health-threatening disease that may be increasingly frequent. However, accurate and representative data on time trends in its incidence and prognosis are not available. This study aims to provide nationwide population-based estimates of alcoholic hepatitis incidence and mortality in Denmark, 1999-2008.
METHODS: We identified, from the Danish National Registry of Patients, all patients with a first-time discharge diagnosis of alcoholic hepatitis from 1999 and through 2008. We also ascertained whether patients had cirrhosis. We computed the annual incidence rates as well as 28-, 84-day, 5-year, and 10-year mortality rates.
RESULTS: We found 1951 patients with alcoholic hepatitis, 63% men. During the study decade, the annual incidence rate in the Danish population rose from 37 to 46 per 10(6) for men and from 24 to 34 per 10(6) for women. The steepest increase was observed among middle-aged women. The 28-day mortality rate rose from 12% to 15%, and the 84-day mortality rate rose from 14% to 24%, similarly for men and women. The increase in short-term mortality was attributable to increasing patient age and prevalence of cirrhosis. The 5-year mortality was 56% overall, 47% without cirrhosis, and 69% with cirrhosis.
CONCLUSIONS: The incidence of alcoholic hepatitis in Denmark has increased during the recent decade. The patients are older at diagnosis and more have cirrhosis, resulting in worse short-term prognosis. The long-term prognosis is grave, especially for patients with cirrhosis. The increase in incidence mirrors changes in alcohol consumption in Denmark.
Copyright © 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21126790     DOI: 10.1016/j.jhep.2010.07.016

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  49 in total

1.  Effects of Clostridium difficile infection in patients with alcoholic hepatitis.

Authors:  Vinay Sundaram; Folasade P May; Vignan Manne; Sammy Saab
Journal:  Clin Gastroenterol Hepatol       Date:  2014-03-27       Impact factor: 11.382

Review 2.  Alcoholic hepatitis: Towards an era of personalised management.

Authors:  Delphine Degré; Line C Ntandja Wandji; Christophe Moreno; Alexandre Louvet
Journal:  United European Gastroenterol J       Date:  2020-07-27       Impact factor: 4.623

3.  A Combination of N-Acetylcysteine and Prednisone Has No Benefit Over Prednisone Alone in Severe Alcoholic Hepatitis: A Retrospective Analysis.

Authors:  Waseem Amjad; Joseph Alukal; Iliana Doycheva; Talan Zhang; Anurag Maheshwari; Hwan Yoo; Paul J Thuluvath
Journal:  Dig Dis Sci       Date:  2020-02-18       Impact factor: 3.199

4.  Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia.

Authors:  David W Crabb; Ramon Bataller; Naga P Chalasani; Patrick S Kamath; Michael Lucey; Philippe Mathurin; Craig McClain; Arthur McCullough; Mack C Mitchell; Timothy R Morgan; Laura Nagy; Svetlana Radaeva; Arun Sanyal; Vijay Shah; Gyongyi Szabo
Journal:  Gastroenterology       Date:  2016-02-24       Impact factor: 22.682

5.  An Open-Label, Dose-Escalation Study to Assess the Safety and Efficacy of IL-22 Agonist F-652 in Patients With Alcohol-associated Hepatitis.

Authors:  Juan P Arab; Tejasav S Sehrawat; Douglas A Simonetto; Vikas K Verma; Dechun Feng; Tom Tang; Kevin Dreyer; Xiaoqiang Yan; William L Daley; Arun Sanyal; Naga Chalasani; Svetlana Radaeva; Liu Yang; Hugo Vargas; Mauricio Ibacache; Bin Gao; Gregory J Gores; Harmeet Malhi; Patrick S Kamath; Vijay H Shah
Journal:  Hepatology       Date:  2020-04-27       Impact factor: 17.425

6.  The costs of hazardous alcohol consumption in Germany.

Authors:  Tobias Effertz; Frank Verheyen; Roland Linder
Journal:  Eur J Health Econ       Date:  2016-08-20

Review 7.  Pathogenesis and Management of Alcoholic Liver Disease.

Authors:  M Omar Farooq; Ramon Bataller
Journal:  Dig Dis       Date:  2016-05-11       Impact factor: 2.404

8.  Design and rationale of a multicenter defeat alcoholic steatohepatitis trial: (DASH) randomized clinical trial to treat alcohol-associated hepatitis.

Authors:  Srinivasan Dasarathy; Mack C Mitchell; Bruce Barton; Craig J McClain; Gyongyi Szabo; Laura E Nagy; Svetlana Radaeva; Arthur J McCullough
Journal:  Contemp Clin Trials       Date:  2020-07-31       Impact factor: 2.226

9.  Hepatitis C as a prognostic indicator among noncirrhotic patients hospitalized with alcoholic hepatitis.

Authors:  Paul J Thuluvath; Eric Ahn; Geoffrey C Nguyen
Journal:  Can J Gastroenterol       Date:  2013-09-13       Impact factor: 3.522

Review 10.  Immune dysfunction in acute alcoholic hepatitis.

Authors:  Ashwin D Dhanda; Peter L Collins
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.